AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$68.29
pos +0.08
+0.12%
Today's Range: 67.49 - 69.00 | ABBV Avg Daily Volume: 10,841,500
Last Update: 07/06/15 - 11:53 AM EDT
Volume: 2,273,386
YTD Performance: 4.23%
Open: $67.53
Previous Close: $68.21
52 Week Range: $51.37 - $70.76
Oustanding Shares: 1,593,076,097
Market Cap: 108,663,720,576
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 8 7
Moderate Buy 0 0 0 0
Hold 2 2 1 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.36 1.40 1.22 1.60
Latest Dividend: 0.51
Latest Dividend Yield: 2.99%
Dividend Ex-Date: 07/13/15
Price Earnings Ratio: 60.90
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
60.90 60.40 26.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.65% 17.38% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $1.06 $1.09 $4.27 $5.06
Number of Analysts 6 4 8 8
High Estimate $1.07 $1.11 $4.33 $5.38
Low Estimate $1.05 $1.05 $4.20 $4.75
Prior Year $0.82 $0.89 $3.32 $4.27
Growth Rate (Year over Year) 29.27% 22.19% 28.46% 18.73%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Chris Laudani

 | Jun 24, 2015 | 1:00 PM EDT

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

By

Jim Cramer

 | Jun 11, 2015 | 2:18 PM EDT

New companies are coming up with major drugs.

bullishAbbvie added to Franchise Pick List at Jefferies

Jun 8, 2015 | 7:10 AM EDT

ABBV was placed on the Franchise Pick list, according to Jefferies. $90 price target. Estimates also increased, given a likely delay in Humira biosimilars. 

By

Robert Lang

 | May 28, 2015 | 10:00 AM EDT

The ABBV chart looks constructive, with solid volume and bullish indicators.

By

Jim Cramer

 | May 26, 2015 | 12:34 PM EDT

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

By

Jim Cramer

 | May 18, 2015 | 12:19 PM EDT

Many of these stocks are off to the races.

By

Jim Cramer

 | May 15, 2015 | 3:11 PM EDT

With a weak dollar, calm oil and tame rates, we're doing fine.

By

Jill Malandrino

 | May 14, 2015 | 3:51 PM EDT

Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.

By

Sham Gad

 | May 11, 2015 | 12:00 PM EDT

The market is a very happy place these days, so be careful.

Hi all, good morning. Back in the office again today. Greece? Great musical. Markets have ...
With the suspension of IPOs by the Chinese authorities, will the "go private" offers withe...
The morning is going to be dominated by the ramifications by the No vote in Greece over th...
If the pattern of the last six years holds, you do revisit the low on the futures so even ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.